Applying antimicrobial pharmacodynamics to resistant gram-negative pathogens

American Journal of Health-System Pharmacy

Volumn 63, Issue 14, 2006, Pages 1346-1360

  Scheetz, Marc H ^a   Hurt, Kristin M ^a   Noskin, Gary A ^b   Oliphant, Catherine M ^c  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c IDAHO STATE UNIVERSITY   (United States)

Author keywords

Aminoglycosides; Antiinfective agents; Carbapenems; Drug use; Glycylcyclines; Methodology; Pharmacodynamics; Pharmacokinetics; Polymyxins; Quinolones; Rational therapy; Resistance; Tetracyclines

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFALOTIN; CEFAZOLIN; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DEMECLOCYCLINE; DOXYCYCLINE; GLYCYLCYCLINE DERIVATIVE; LINCOSAMIDE; MACROLIDE; MINOCYCLINE; NITROFURANTOIN; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTEREMIA; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONCENTRATION RESPONSE; DRUG BINDING SITE; ENZYME DEGRADATION; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 33746353088     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050403     Document Type: Review

References (132)

1. National Institute of Allergy and Infectious Diseases. The problem of antibiotic resistance. www.niaid.nih.gov/factsheets/antimicro.htm (accessed 2006 April).
2. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. www.cdc.gov/ncidod/dhap/pdf/nnis/ 2004NNISreport.pdf (accessed 2006 Apr 11).
3. Infectious Diseases Society of America. Bad bugs, no drugs. As antibiotic discovery stagnates ... a public health crisis brews. www.idsociety.org/pa/ IDSA_ Paper4_final_web.pdf (accessed 2005 Jul 11).
4. Infectious Diseases Society of America. Facts about the antibiotic R&D pipeline: why antibiotics require special treatment. www.idsociety.org/Template. cfm?Section=Antimicrobials& Template=/ ContentManagement/ContentDisplay.cfm&ContentID=9715 (accessed 2005 Jul 13).
5. Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001; 134:298-314.
6. Kollef MH, Sherman G, Ward S et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest. 1999; 115:462-74.
7. Gruson D, Hubert G, Vargas F et al. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of gram-negative bacilli responsible for ventilator-associated pneumonia. Crit Care Med. 2003; 31:1908-14.
8. Gruson D, Hubert G, Vargas F et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med. 2000; 162:837-43.
9. Raymond DP, Pelletier SJ, Crabtree TD et al. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med. 2003; 31:1035-41.
10. Craven DE, Palladino R, McQuillen DP. Healthcare-associated pneumonia in adults: management principles to improve outcomes. Infect Dis Clin North Am. 2004; 18:939-62.
11. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin Infect Dis. 2003; 36(suppl 1):S11-23.
12. Howard DH, Scott RD II, Packard R et al. The global impact of drug resistance. Clin Infect Dis. 2003; 36(suppl 1):S4-10.
13. Infectious Diseases Society of America. Bad bugs, no drugs Executive Summary. www.idsociety.org/Template.cfm? Section=Antimicrobials&Template=/ ContentManagement/ContentDisplay. cfm&ContentID=9770 (accessed 2005 Jul 11).
14. Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004; 38:1279-86.
15. Waterer GW, Wunderink RG. Increasing threat of gram-negative bacteria. Crit Care Med. 2001; 29(4 suppl):N75-81.
16. Normark BH, Normark S. Evolution and spread of antibiotic resistance. J Intern Med. 2002; 252:91-106.
17. Hawkey PM. The origins and molecular basis of antibiotic resistance. BMJ. 1998; 317:657-60.
18. Tenover FC. Development and spread of bacterial resistance to antimicrobial agents: an overview. Clin Infect Dis. 2001; 33(suppl 3):S108-15.
19. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001; 7:337-41.
20. Opal SM, Mayer KH, Medeiros AA. Mechanisms of bacterial antibiotic resistance. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingstone; 2000:236-48.
21. Neu HC. Penicillin-binding proteins and beta-lactamases: their effects on the use of cephalosporins and other new beta-lactams. Curr Clin Top Infect Dis. 1987; 8:37-61.
22. Medeiros AA. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis. 1997; 24(suppl 1):S19-45.
23. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents. Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am. 2000; 14:293-319.
24. Essack SY. The development of beta-lactam antibiotics in response to the evolution of beta-lactamases. Pharm Res. 2001; 18:1391-9.
25. Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001; 32:1085-9.
26. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995; 39:1211-33.
27. Lee NL, Yuen KY, Kumana CR. Beta-lactam antibiotic and beta-lactamase inhibitor combinations. JAMA. 2001; 285:386-8.
28. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995; 8:557-84.
29. Corvee S, Caroff N, Espaze E et al. AmpC cephalosporinase hyperproduction in Acinetobacter baumannii clinical strains. J Antimicrob Chemother. 2003; 52:629-35.
30. Sturenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003; 47:273-95.
31. Livermore DM. Acquired carbapenemases. J Antimicrob Chemother. 1997; 39:673-6.
32. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol. 2000; 3:489-95.
33. Peleg AY, Franklin C, Bell JM et al. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis. 2005; 41:1549-56.
34. Rasmussen BA, Bush K. Carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother. 1997; 41:223-32.
35. Samaha-Kfoury JN, Araj GF. Recent developments in beta lactamases and extended spectrum beta lactamases. BMJ. 2003; 327:1209-13.
36. Nathisuwan S, Burgess DS, Lewis JS II. Extended-spectrum beta-lactamases: epidemiology, detection, and treatment. Pharmacotherapy. 2001; 21:920-8.
37. Meyer KS, Urban C, Eagan JA et al. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med. 1993; 119:353-8.
38. Burgess DS, Hall RG II, lewis JS II et al. Clinical and microbiologic analysis of a hospital's extended-spectrum beta-lactamase-producing isolates over a 2-year period. Pharmacotherapy. 2003; 23:1232-7.
39. Kang CI, Kim SH, Park WB et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother. 2004; 48:4574-81.
40. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001; 45:3548-54.
41. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement, M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
42. Philippon A, Ariel G, Jacoby GA. Plasmid-determined AmpC-type beta-lactamases. Antimicrob Agents Chemother. 2002; 46:1-11.
43. Hanson ND. AmpC beta-lactamases: what do we need to know for the future? J Antimicrob Chemother. 2003; 52:2-4.
44. Coudron PE, Hanson ND, Climo MW. Occurrence of extended-spectrum and AmpC beta-lactamases in bloodstream isolates of Klebsiella pneumoniae: isolates harbor plasmid-mediated FOX-5 and ACT-1 AmpC beta-lactamases. J Clin Microbiol. 2003; 41:772-7.
45. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 1996; 335:1445-53.
46. Jakics EB, Iyobe S, Hirai K et al. Occurrence of the nfxB type mutation in clinical isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1992; 36:2562-5.
47. Centers for Disease Control and Prevention. Fact sheet: 12 steps to prevent antimicrobial resistance among hospitalized adults, www.cdc.gov/ drugresistance/healthcare/ha/12steps_HA.htm (accessed 2005 May 18).
48. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. CLSI document M100-S15. Wayne, PA: Clinical and laboratory Standards Institute; 2005.
49. Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline, second edition. NCCLS document M23-A2. Wayne, PA: National Committee for Clinical Laboratory Standards; 2001.
50. MacGowan AP, Wise R. Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 2001; 48(suppl 1):17-28.
51. Kuti JL, Dandekar PK, Nightingale CH et al. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol. 2003; 43:1116-23.
52. Lomaestro BM, Drusano GL. Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother. 2005; 49:461-3.
53. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002. Antimicrob Agents Chemother. 2004; 48:2464-70.
54. Bradley JS, Dudley MN, Drusano GL. Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation. Pediatr Infect Dis J. 2003; 22:982-92.
55. Liu P, Derendorf H. Antimicrobial tissue concentrations. Infect Dis Clin North Am. 2003; 17:599-613.
56. Chambers HF, Mills J, Drake TA et al. Failure of a once-daily regimen of cefonicid for treatment of endocarditis due to Staphylococcus aureus. Rev Infect Dis. 1984; 6(suppl 4):S870-4.
57. Mueller M, de la Pena A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother. 2004; 48:369-77.
58. Lamer C, de Beco V, Soler P et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother. 1993; 37:281-6.
59. Georges H, Leroy O, Alfandari S et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis. 1997; 16:385-8.
60. Lovering AM, Walsh TR, Bannister GC et al. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimicrob Chemother. 2001; 47:483-6.
61. Wagenlehner FM, Weidner W, Sorgel F et al. The role of antibiotics in chronic bacterial prostatitis. Int J Antimicrob Agents. 2005; 26:1-7.
62. Cooper GL, Given DB. Vancomycin: a comprehensive review of 30 years of clinical experience. Indianapolis: Park Row; 1986.
63. Joly V, Pangon B, Vallois JM et al. Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis. Antimicrob Agents Chemother. 1987; 31:1632-9.
64. McKinnon PS, Davis SL. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol Infect Dis. 2004; 23:271-88.
65. Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clin Pharmacokinet. 1993; 24:496-506.
66. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. J Antimicrob Chemother. 2001; 48(suppl 1):87-102.
67. Levison ME. Pharmacodynamics of antimicrobial drugs. Infect Dis Clin North Am. 2004; 18:451-65.
68. Pearson RD, Steigbigel RT, Davis HT et al. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980; 18:699-708.
69. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1-10.
70. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl. 1990; 74:63-70.
71. Hyatt JM, McKinnon PS, Zimmer GS et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995; 28:143-60.
72. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr. 1986; 108(5, pt. 2):835-40.
73. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol. 2001; 52(suppl 1):35S-43S.
74. Craig WA. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother. 1993; 31(suppl D):149-58.
75. Fantin B, Ebert S, Leggett J et al. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli. J Antimicrob Chemother. 1991; 27:829-36.
76. Vogelman B, Gudmundsson S, Turnidge J et al. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis. 1988; 157:287-98.
77. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis. 1995; 22:89-96.
78. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003; 17:479-501.
79. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995; 39:650-5.
80. Nix DE, Goodwin SD, Peloquin CA et al. Antibiotic tissue penetration and its relevance: impact of tissue penetration on infection response. Antimicrob Agents Chemother. 1991; 35:1953-9.
81. Kuti J, Nicolau D. Application of pharmacodynamic principles: from theory to practice. In: Owens R, Ambrose P, Nightingale C, eds. Antibiotic optimization: concepts and strategies in clinical practice. New York: Marcel Dekker; 2005:353-82.
82. McNabb JJ, Bui KQ. Beta-lactam pharmacodynamics. In: Nightingale CH, Murakawa T, Ambrose PG, eds. Antimicrobial pharmacodynamics in theory and clinical practice. 1st ed. New York: Marcel Dekker; 2002:99-123.
83. Nishida M, Murakawa T, Kamimura T et al. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Antimicrob Agents Chemother. 1978; 14:6-12.
84. Andes D, Craig W. Understanding pharmacokinetics and pharmacodynamics: application to the antimicrobial formulary decision process. In: Owens R, Ambrose P, Nightingale C, eds. Antibiotic optimization: concepts and strategies in clinical practice. New York: Marcel Dekker; 2005:65-88.
85. Kasiakou SK, Lawrence KR, Choulis N et al. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systematic review of pharmacokinetic and pharmacodynamic parameters. Drugs. 2005; 65:2499-511.
86. Mouton JW, Touzw DJ, Horrevorts AM et al. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet. 2000; 39:185-201.
87. Mouton JW. Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am. 2003; 17:579-98.
88. Drusano GL, Johnson DE, Rosen M et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother. 1993; 37:483-90.
89. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA. 1998; 279:125-9.
90. Blaser J, Stone BB, Groner MC et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987; 31:1054-60.
91. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother. 1994; 38:2730-7.
92. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993; 37:1073-81.
93. Madaras-Kelly KJ, Ostergaard BE, Hovde IB et al. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1996; 40:627-32.
94. Thomas JK, Forrest A, Bhavnani SM et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 1998; 42:521-7.
95. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003; 112:275-85.
96. Tam VH, Louie A, Deziel MR et al. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J Infect Dis. 2005; 192:420-8.
97. Shargel L, Yu A. Applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk, CT: Appleton & Lange; 1993.
98. McCormack JP, Jewesson PJ. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992; 14:320-39.
99. Daikos GL, Lolans VT, Jackson GG. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. Antimicrob Agents Chemother. 1991; 35:117-23.
100. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother. 2002; 46:1481-91.
101. Kashuba AD, Nafziger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999; 43:623-9.
102. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987; 155:93-9.
103. Panidis D, Markantonis SL, Boutzouka E et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005; 128:545-52.
104. McCormack JP. An emotional-based medicine approach to monitoring once-daily aminoglycosides. Pharmacotherapy. 2000; 20:1524-7.
105. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984; 149:443-8.
106. Hermsen ED, Sullivan CJ, Rotschafer JC. Polymyxins: pharmacology, pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin North Am. 2003; 17:545-62.
107. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005; 40:1333-41.
108. Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999; 33:960-7.
109. McMillan FH, Pattison IC. Sodium colistimethate. I. Dissociations of aminomethanesulfonates in aqueous solution. J Pharm Sci. 1969; 58:730-7.
110. Li J, Milne RW, Nation RL. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003; 47:1364-70.
111. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multiresistant gram-negative bacteria. Int J Antimicrob Agents. 2005; 25:11-25.
112. Li J, Turnidge J, Milne R et al. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001; 45:781-5.
113. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999; 43:1317-23.
114. Catchpole CR, Andrews JM, Brenwald N et al. A reassessment of the in-vitro activity of colistin sulphomethate sodium. J Antimicrob Chemother. 1997; 39:255-60.
115. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol. 2001; 39:183-90.
116. Vila J, Marcos A, Marco F et al. In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii, Antimicrob Agents Chemother. 1993; 37:138-41.
117. Cisneros JM, Reyes MJ, Pachon J et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996; 22:1026-32.
118. Gales AC, Jones RN, Forward KR et al. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). Clin Infect Dis. 2001; 32(suppl 2):S104-13.
119. Rodriguez-Hernandez MJ, Pachon J, Pichardo C et al. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J Antimicrob Chemother. 2000; 45:493-501.
120. Wood GC, Hanes SD, Boucher BA et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003; 29:2072-6.
121. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother. 2004; 38:1449-59.
122. Smilack JD. The tetracyclines. Mayo Clin Proc. 1999; 74:727-9.
123. Zhanel GG, Homenuik K, Nichol K et al. The glycylcyclines: a comparative review with the tetracyclines. Drugs. 2004; 64:63-88.
124. Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycyline. Clin Microbiol Infect. 2000; 6:270-3.
125. Garrison MW, Neumiller JJ, Setter SM. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms. Clin Ther. 2005; 27:12-22.
126. Pachon-Ibanez ME, Jimenez-Mejias ME, Pichardo C et al. Activity of tigecycline (GAR-936) against Acinetobacter baumannii strains, including those resistant to imipenem. Antimicrob Agents Chemother. 2004; 48:4479-81.
127. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002; 49:479-87.
128. Van Ogtrop ML, Andes D, Stamstar TJ et al. In vivo pharmacodynamics activities of two glycylcyclines (GAR-936 and WAY 152,288) againist various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000; 44:943-9.
129. Meagher A, Passarell J, Cirincione B et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections. Presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark; 2005 Apr 4.
130. Passarell J, Liolios K, Meagher A et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated intra-abdominal infections. Paper presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2005 Dec 17.
131. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998; 27:10-22.
132. Boselli E, Breilh D, Rimmele T et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004; 30:989-91.